Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Expected currency impact for full year 2022 Currency impact vs. PY %pts, assuming late-January exchange rates prevail in 2022 FX impact on Net sales 2 | FX impact on Core operating income 2 I -2 Q4 2021 FY Actual Simulation 47 Investor Relations | Q4 2021 Results I I -3 -3 -4 -4 -5 | Q1 2022 FY Q4 FY Q1 FY I 2021 2022 NOVARTIS | Reimagining Medicine

View entire presentation